Literature DB >> 7559308

Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.

P J Lombroso1, L Scahill, R A King, K A Lynch, P B Chappell, B S Peterson, C J McDougle, J F Leckman.   

Abstract

OBJECTIVE: The purpose of this trial was to investigate the short-term safety and efficacy of risperidone in the treatment of chronic tic disorders in children and adolescents.
METHOD: This was an 11-week open-label trial and included seven subjects (five boys and two girls) with a mean age of 12.9 +/- 1.9 years. The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder. The children were seen at baseline and for two follow-up visits. Three children had a comorbid diagnosis of obsessive-compulsive disorder (OCD).
RESULTS: Clinical response, as measured by the Yale Global Tic Severity Scale and the Children's version of the Yale-Brown Obsessive Compulsive Scale, revealed a statistically significant reduction in tic scores ranging from 26% [corrected] to 66%. One of three children with comorbid OCD showed substantial improvement; the other two subjects showed no change. The most frequent side effect was weight gain, which ranged from 8 to 14 lb.
CONCLUSIONS: Risperidone, a neuroleptic with both serotonin- and dopamine-blocking properties, appears to be effective in reducing tic frequency and intensity in children and adolescents with chronic tic disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559308     DOI: 10.1097/00004583-199509000-00011

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  24 in total

Review 1.  Stuttering: an update for physicians.

Authors:  D Costa; R Kroll
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

Review 2.  Tourette syndrome: clinical characteristics and current management strategies.

Authors:  E H Kossoff; H S Singer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Bridging neuroscience and clinical psychology: cognitive behavioral and psychophysiological models in the evaluation and treatment of Gilles de la Tourette syndrome.

Authors:  Marc E Lavoie; Julie Leclerc; Kieron P O'Connor
Journal:  Neuropsychiatry (London)       Date:  2013-02-01

Review 4.  Gilles de la Tourette syndrome: symptomatic treatment based on evidence.

Authors:  M M Robertson; J S Stern
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 5.  Bodyweight gain with atypical antipsychotics. A comparative review.

Authors:  T Wetterling
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

Review 6.  The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.

Authors:  Guy Chouinard
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

Review 7.  The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.

Authors:  Cathy L Budman
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

8.  Aripiprazole for the treatment of Tourette's disorder.

Authors:  Prasad R Padala; S Faiz Qadri; Vishal Madaan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 9.  Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Authors:  Kimberly A Stigler; Marc N Potenza; David J Posey; Christopher J McDougle
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 10.  Contemporary assessment and pharmacotherapy of Tourette syndrome.

Authors:  Lawrence Scahill; Gerald Erenberg; Cheston M Berlin; Cathy Budman; Barbara J Coffey; Joseph Jankovic; Louise Kiessling; Robert A King; Roger Kurlan; Anthony Lang; Jonathan Mink; Tanya Murphy; Samual Zinner; John Walkup
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.